Secunderabad Chronicle

Food Allergy Pipeline Landscape Analysis of 30+ Companies by DelveInsight

 Breaking News
  • No posts were found

Food Allergy Pipeline Landscape Analysis of 30+ Companies by DelveInsight

October 11
18:10 2022
Food Allergy Pipeline Landscape Analysis of 30+ Companies by DelveInsight

DelveInsight’s, “Food Allergy Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in the Food Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Food Allergy Pipeline Report

  • DelveInsight’s Food Allergy Pipeline report depicts a robust space with 30+ active players working to develop 35+ pipeline therapies for Food Allergy treatment.
  • The leading Food Allergy Companies include such as Merck & Co, DBV technologies, Genentech, Camallergy, Regeneron Pharmaceuticals, InnoUp Farma, Aravax, Inimmune, Novartis Pharmaceuticals, Astrazeneca, Cour Pharmaceuticals, Siolta Therapeutics, Vedanta Biosciences, Mabylon, GI Innovation, and others are developing potential drug candidates to improve the Food Allergy treatment scenario.
  • The promising Food Allergy Therapies in the pipeline includes such as Viaskin Peanut/DBV712, CA002, Omalizumab, Ligelizumab, AR201, Dupixent, Viaskin Milk, ADP101, IgGenix, and others.
  • A detailed portfolio of major pharma players who are involved in fueling the Food Allergies treatment market. Several potential therapies for Food Allergies are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Food Allergies market size in the coming years. 

 

Get an overview of the pipeline landscape @ Food Allergy Pipeline Outlook

 

Food Allergy Overview

A food allergy occurs when the body’s immune system sees a certain food as harmful and reacts by causing symptoms. This is an allergic reaction. Foods that cause allergic reactions are allergens. The results of skin prick tests (SPT), IgE total and specific antibodies, and patient histories are not predictive of true food allergy, as they are not able to establish the causal and temporal relationship between the intake of the suspect food and the hypersensitivity reaction. The negative predictive accuracy of a skin prick test weal of < 3mm greater than the negative control is high, usually > 95%, and is strong evidence that the food may be consumed without severe, immediate food-allergic reactions.

A positive SPT, even a weal of 3 mm or more, may be clinically irrelevant, as the patient may tolerate the ingested food. SPTs may also remain positive after the development of tolerance to the specific food. The foods to which an individual is allergic should be avoided, as therapeutic intervention (tertiary prevention) in patients with food allergy.  It must strike a precautionary equilibrium between the demands of prohibitive measures against allergy care and quality of life. Hypersensitivity reactions are often treated with medications. . Epinephrine is the only medication that is effective for the treatment of anaphylaxis. Additional medications include H1 and H2 antihistamines, corticosteroids, and prostaglandin synthetase inhibitors.

 

Latest Breakthroughs and Developments in the Food Allergy Treatment Landscape

  • In September 2018, a new prefilled syringe formulation of this drug was approved by the FDA. Genentech and Novartis Pharmaceuticals Corporation are working closely with NIAID and the Consortium of Food Allergy Research to start a potentially pivotal study assessing the efficacy and safety of Xolair in multiple food allergies. It is currently being evaluated in the Phase III stage of development for treating Peanut Allergy patients.
  • Dupilumab is a human monoclonal antibody that is an interleukin-4 (IL-4) receptor alpha antagonist. Dupilumab is designed by Regeneron using VelocImmune® technology. It is an immunoglobulin G4 subclass human monoclonal antibody that work by blocking the IL-4 and interleukin-13 (IL-13) signalling by binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. It is a potential monotherapy administered subcutaneously to the pedantic patients with peanut allergy.
  • Investigational Viaskin® Peanut therapeutic treatment is based on epicutaneous immunotherapy, or EPIT™.   This potential new class of immunotherapey is designed to work by delivering allergens to the immune system through intact skin using our proprietary Viaskin® technology. For those patients facing potentially life-threatening food allergies, this potential immunotherapy treatment aims to desensitize them to allergens by delivering compounds in small quantities into the outer layers of the skin. The investigational EPIT aims to target specific epidermal dendritic cells, called Langerhans cells. Pre-clinical research has shown that these cells capture antigens and migrate to the lymph node in order to activate the immune system.
  • ADP101 is a proprietary, standardized, oral immunotherapy drug candidate that is being studied for the treatment of food allergy to one or more foods. ADP101 is formulated to consistently deliver a well-characterized investigational drug product sourced from the most commonly allergenic food groups and designed to be administered as part of a clinically monitored dosing protocol. The goal of oral immunotherapy is to induce a state of clinically meaningful desensitization to food proteins, defined as the absence of moderate or severe allergic reaction following the ingestion of small but potentially dangerous amounts of food. ADP101 is based on an intellectual property estate that includes patents and accompanying clinical data licensed from Stanford University.

 

Food Allergy Emerging Drugs

  • Viaskin Peanut: DBV technologies
  • Omalizumab: Genentech
  • Dupilumab: Regeneron Pharmaceuticals
  • ADP101: Alladapt Immunotherapeutics

 

Food Allergy Pipeline Therapeutics Analysis

There are approx. 30+ key companies which are developing the therapies for Food Allergies. The companies which have their Food Allergies drug candidates in the most advanced stage, i.e. preregistration include, DBV technologies.

 

For further information, refer to the detailed report @ Food Allergy Emerging Therapies

 

DelveInsight’s Food Allergy Pipeline Report covers around 35+ products under different phases of clinical development like-

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Scope of the Food Allergy Pipeline Report

  • Coverage- Global
  • Food Allergy Companies- Merck & Co, DBV technologies, Genentech, Camallergy, Regeneron Pharmaceuticals, InnoUp Farma, Aravax, Inimmune, Novartis Pharmaceuticals, Astrazeneca, Cour Pharmaceuticals, Siolta Therapeutics, Vedanta Biosciences, Mabylon, GI Innovation, and others.
  • Food Allergy Therapies- Viaskin Peanut/DBV712, CA002, Omalizumab, Ligelizumab, AR201, Dupixent, Viaskin Milk, ADP101, IgGenix, and others
  • Food Allergy Therapeutic Assessment by Product Type
  • Food Allergy Therapeutic Assessment by Stage and Product Type
  • Food Allergy Therapeutic Assessment by Route of Administration
  • Food Allergy Therapeutic Assessment by Stage and Route of Administration
  • Food Allergy Therapeutic Assessment by Molecule Type
  • Food Allergy Therapeutic Assessment by Stage and Molecule Type
  • Food Allergy companies’ collaborations, Licensing, Acquisition -Deal Value Trends

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Food Allergies: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Food Allergies – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Viaskin Peanut: DBV technologies
  9. Mid Stage Products (Phase II)
  10. Dupilumab: Regeneron
  11. Early Stage Products (Phase I/II)
  12. ADP101: Alladapt Immunotherapeutics
  13. Preclinical and Discovery Stage Products
  14. Research programme: antiallergy therapeutics: IgGenix
  15. Inactive Products
  16. Food Allergies Key Companies
  17. Food Allergies Key Products
  18. Food Allergies- Unmet Needs
  19. Food Allergies- Market Drivers and Barriers
  20. Food Allergies- Future Perspectives and Conclusion
  21. Food Allergies Analyst Views
  22. Food Allergies Key Companies
  23. Appendix

 

Got Queries? Reach out for more information on the Food Allergies Pipeline Report- Food Allergies Pipeline Therapeutic Assessment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles